{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:35:49Z","timestamp":1774985749585,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>A paradoxical GH rise after the glucose load (GH-Par) is described in about one-third of acromegalic patients. Here, we evaluated the GH profile in subjects with and without acromegaly aiming to refine the definition of GH-Par.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>Observational case\u2013control study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our cohort consisted of 60 acromegalic patients, and two groups of subjects presenting suppressed GH (&lt;\u20090.4\u00a0\u00b5g\/L) and high (non-acro<jats:sup>\u2191IGF\u22121<\/jats:sup>, n\u2009=\u2009116) or normal IGF-1 levels (non-acro, n\u2009=\u200955). The distribution of GH peaks\u2009\u2265\u2009120% from baseline, insulin, and glucose levels were evaluated over a 180-min time interval after glucose intake.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A similar proportion of subjects in all three groups shows a GH ratio of\u2009\u2265\u2009120% starting from 120\u00a0min. Re-considering the definition of paradoxical increase of GH within 90\u00a0min, we observed that the prevalence of GH peaks\u2009\u2265\u2009120% was higher in acromegaly than in non-acro<jats:sup>\u2191IGF\u22121<\/jats:sup> and non-acro (respectively 42%, 16%, and 7%, both p\u2009&lt;\u20090.001). In patients without GH-Par, a late GH rebound was observed in the second part of the curve. Higher glucose peak (p\u2009=\u20090.038), slower decline after load, 20% higher glucose exposure (p\u2009=\u20090.015), and a higher prevalence of diabetes (p\u2009=\u20090.003) characterized acromegalic patients with GH-Par (with respect to those without).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GH-Par response may be defined as a 20% increase in the first 90\u00a0min after glucose challenge. GH-Par, common in acromegaly and associated with an increased prevalence of glucose metabolism abnormalities, is found also in a subset of non-acromegalic subjects with high IGF-1 levels, suggesting its possible involvement in the early phase of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02138-9","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:03:17Z","timestamp":1687366997000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Paradoxical GH increase after oral glucose load in subjects with and without acromegaly"],"prefix":"10.1007","volume":"47","author":[{"given":"F.","family":"Ceccato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. K.","family":"Vedolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Regazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4065-4677","authenticated-orcid":false,"given":"G.","family":"Occhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"5","key":"2138_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.beem.2009.05.010","volume":"23","author":"P Chanson","year":"2009","unstructured":"Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23(5):555\u2013574. https:\/\/doi.org\/10.1016\/j.beem.2009.05.010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2138_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509\u20131517","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"2138_CR3","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Acromegaly. N Engl J Med 355(24):2558\u20132573. https:\/\/doi.org\/10.1056\/NEJMra062453","journal-title":"N Engl J Med"},{"issue":"7","key":"2138_CR4","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141\u20133148. https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2138_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/jama.1967.03130080070021","volume":"201","author":"JM Earll","year":"1967","unstructured":"Earll JM, Sparks LL, Forsham PH (1967) Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA 201(8):628\u2013630","journal-title":"JAMA"},{"issue":"5","key":"2138_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1210\/jc.2018-00975","volume":"104","author":"K Mukai","year":"2019","unstructured":"Mukai K, Otsuki M, Tamada D et al (2019) Clinical characteristics of acromegalic patients with paradoxical GH response to oral glucose load. J Clin Endocrinol Metab 104(5):1637\u20131644. https:\/\/doi.org\/10.1210\/jc.2018-00975","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2138_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1530\/EJE-21-0324","volume":"185","author":"V Atquet","year":"2021","unstructured":"Atquet V, Alexopoulou O, Maiter D (2021) Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load. Eur J Endocrinol 185(2):313\u2013321. https:\/\/doi.org\/10.1530\/EJE-21-0324","journal-title":"Eur J Endocrinol"},{"key":"2138_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2022.101501","author":"H D\u00fc\u011fer","year":"2022","unstructured":"D\u00fc\u011fer H, Bostan H, Deryol HY et al (2022) Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients. Growth Horm IGF Res. https:\/\/doi.org\/10.1016\/j.ghir.2022.101501","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2138_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1210\/jc.2018-01360","volume":"104","author":"C Scaroni","year":"2019","unstructured":"Scaroni C, Albiger N, Daniele A et al (2019) Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 104(3):856\u2013862. https:\/\/doi.org\/10.1210\/jc.2018-01360","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2138_CR10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1210\/jc.2018-01504","volume":"104","author":"M Hage","year":"2019","unstructured":"Hage M, Chalign\u00e9 R, Viengchareun S et al (2019) Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas. J Clin Endocrinol Metab 104(5):1777\u20131787. https:\/\/doi.org\/10.1210\/jc.2018-01504","journal-title":"J Clin Endocrinol Metab"},{"key":"2138_CR11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0831","author":"D Regazzo","year":"2017","unstructured":"Regazzo D, Losa M, Albiger NM et al (2017) The GIP\/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp-somatotropinomas. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-16-0831","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2138_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1507\/endocrj.50.643","volume":"50","author":"M Umahara","year":"2003","unstructured":"Umahara M, Okada S, Ohshima K, Mori M (2003) Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocr J 50(5):643\u2013650. https:\/\/doi.org\/10.1507\/endocrj.50.643","journal-title":"Endocr J"},{"issue":"7","key":"2138_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2826.2011.02155.x","volume":"23","author":"G Occhi","year":"2011","unstructured":"Occhi G, Losa M, Albiger N et al (2011) The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrinol 23(7):641\u2013649. https:\/\/doi.org\/10.1111\/j.1365-2826.2011.02155.x","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"2138_CR14","doi-asserted-by":"publisher","first-page":"R261","DOI":"10.1530\/EJE-20-1448","volume":"184","author":"M Hage","year":"2021","unstructured":"Hage M, Janot C, Salenave S, Chanson P, Kamenick\u00fd P (2021) Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Eur J Endocrinol 184(6):R261\u2013R268. https:\/\/doi.org\/10.1530\/EJE-20-1448","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2138_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000497214","volume":"108","author":"M Hage","year":"2019","unstructured":"Hage M, Kamenick\u00fd P, Chanson P (2019) Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology 108(3):244\u2013255. https:\/\/doi.org\/10.1159\/000497214","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2138_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s42000-020-00235-5","volume":"20","author":"F Ceccato","year":"2021","unstructured":"Ceccato F, Barbot M, Lizzul L et al (2021) Clinical presentation and management of acromegaly in elderly patients. Hormones (Athens) 20(1):143\u2013150. https:\/\/doi.org\/10.1007\/s42000-020-00235-5","journal-title":"Hormones (Athens)"},{"key":"2138_CR17","unstructured":"Ceccato F (2022) Paradoxical GH increase after OGTT\u2014repository data. http:\/\/researchdata.cab.unipd.it\/id\/eprint\/640. Accessed 17 May 2022"},{"issue":"1","key":"2138_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11154-019-09536-6","volume":"21","author":"D Regazzo","year":"2020","unstructured":"Regazzo D, Barbot M, Scaroni C, Albiger N, Occhi G (2020) The pathogenic role of the GIP\/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Rev Endocr Metab Disord 21(1):165\u2013183. https:\/\/doi.org\/10.1007\/s11154-019-09536-6","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"2138_CR19","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2138_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00268-007-9408-5","volume":"32","author":"M Iacobone","year":"2008","unstructured":"Iacobone M, Albiger N, Scaroni C et al (2008) The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 32(5):882\u2013889. https:\/\/doi.org\/10.1007\/s00268-007-9408-5","journal-title":"World J Surg"},{"issue":"7","key":"2138_CR21","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1210\/jc.2013-1581","volume":"98","author":"A Ribeiro-Oliveira","year":"2013","unstructured":"Ribeiro-Oliveira A, Abrantes MM, Barkan AL (2013) Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas. J Clin Endocrinol Metab 98(7):2959\u20132966. https:\/\/doi.org\/10.1210\/jc.2013-1581","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2138_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/ERC-21-0258","volume":"29","author":"D Regazzo","year":"2022","unstructured":"Regazzo D, Bertazza L, Galletta E et al (2022) The GIP\/GIPR axis in medullary thyroid cancer: clinical and molecular findings. Endocr Relat Cancer 29(5):273\u2013284. https:\/\/doi.org\/10.1530\/ERC-21-0258","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2138_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000330447","volume":"94","author":"B Waser","year":"2011","unstructured":"Waser B, Beetschen K, Pellegata NS, Reubi JC (2011) Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94(4):291\u2013301. https:\/\/doi.org\/10.1159\/000330447","journal-title":"Neuroendocrinology"},{"key":"2138_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2006.12.034","volume":"265\u2013266","author":"TL Mazzuco","year":"2007","unstructured":"Mazzuco TL, Chabre O, Feige JJ, Thomas M (2007) Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol Cell Endocrinol 265\u2013266:23\u201328. https:\/\/doi.org\/10.1016\/j.mce.2006.12.034","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2138_CR25","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/eje.0.145r001","volume":"145","author":"M Peracchi","year":"2001","unstructured":"Peracchi M, Porretti S, Gebbia C et al (2001) Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. Eur J Endocrinol 145(1):R1\u2013R4","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2138_CR26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2967\/jnumed.113.133744","volume":"55","author":"E Gourni","year":"2014","unstructured":"Gourni E, Waser B, Clerc P, Fourmy D, Reubi JC, Maecke HR (2014) The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging\u2014first preclinical studies. J Nucl Med 55(6):976\u2013982. https:\/\/doi.org\/10.2967\/jnumed.113.133744","journal-title":"J Nucl Med"},{"issue":"5","key":"2138_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11102-020-01055-x","volume":"23","author":"M Barbot","year":"2020","unstructured":"Barbot M, Regazzo D, Mondin A et al (2020) Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary 23(5):534\u2013542. https:\/\/doi.org\/10.1007\/s11102-020-01055-x","journal-title":"Pituitary"},{"key":"2138_CR28","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0296","author":"P Wolf","year":"2022","unstructured":"Wolf P, Dormoy A, Maione L et al (2022) Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Endocr Connect. https:\/\/doi.org\/10.1530\/EC-22-0296","journal-title":"Endocr Connect"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02138-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T19:13:59Z","timestamp":1704827639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02138-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02138-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Institutional and National) and with the Helsinki Declaration of 1964 and later version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}